baiosphere’s Post

We want to hear from you! Let us know your opinions about AI in the comment section of this #Talk2UsTuesday post. Also, if you're interested in breakthrough technology in AMR research, be sure to catch our next Member Spotlight featuring Phase Genomics on July 9th with Ivan Liachko 🇺🇦. #ai #amr #artificialintelligence #antimicrobialresistance #biotech

Video of the day AQEMIA: on Ai Jumble-Listing AI tools, Driving Adoption-Building a thriving AI community🌟 🔬 Explore the groundbreaking world of Aqemia, the next-gen pharma tech company revolutionizing drug discovery. Witness their mission to design fast, innovative drug candidates for critical diseases. 💊 📊Here at AI Jumble, We are creating a vibrant community of AI enthusiasts, developers, researchers, and industry professionals. Want to work with us, collaborate with our cohort or just wanna know more about us - just hit a comment & we will get back to you! Let's create extraordinary spaces together! 💡 🔔 Subscribe now and never miss an episode of AI Jumble, where we explore the fascinating world of artificial intelligence and its impact on our lives. Hit that like button 👍 and share this video with your friends who are passionate about AI! Thanks for watching, and happy Exploring! 🚀 https://lnkd.in/gSBu3GbQ #Aqemia #DrugDiscovery #QuantumPhysics #AIInnovation #PharmaTech #Biotech #CuttingEdgeResearch #InnovativeSolutions #DeepTech #ScienceandTechnology

🌟🎓 What a pleasure to be back at UC San Diego today to discuss new #foundationmodels for #timeseries #forecasting and how they can be used in combination with CybergenX' AI-first data to train a new class of Generative AI models for #EngineeringBiology. At CybergenX, we're committed to pushing the boundaries of what's possible. Today's conversations reaffirmed our mission to leverage AI to transform the way we approach biomanufacturing, opening up new frontiers in the design and optimization of biological processes. Here's to new exciting collaborations and a future where AI and biotechnology come together to create groundbreaking solutions for global challenges. 🌍🚀 #AI #Biotechnology #collaborations #Biodynamics #DataScience #FutureTech

Last week, our PangeAI President Sona Chandra spoke at BioIndustry Association (BIA)'s TechBio Uk Conference about Truly Transformational AI alongside a panel of experts including Joseph Lehár, SVP at Owkin, Rémy Boutonnet, CTO and Co-founder of Turing Biosystems, Aline Charpentier, Head of Innovation at Bruntwood SciTech, and Chris Murray, SVP of Informatics at Astex Pharmaceuticals (UK) . She highlighted the reality of the industry today: most drugs fail in Phase 2 clinical trials due to issues of safety and efficacy. She indicated importance of moving the needle in AI-driven drug discovery by focusing on translation into human biology. This underpins our thesis at Pangea, where we leverage AI to unlock promising chemical starting points from plants and other kingdoms that already have established, strong signals of safety and efficacy in humans due to centuries of medicinal use and phenotypic evidence, thus optimising our chances of success in the clinic. #drugdiscovery #drugdevelopment #AI #biotech #techbiouk #BIA #learnings

#TechBio 2023 UK driving AI #Revolution report is here 👨💻 https://ow.ly/pyTa50PY24i The report is an opportunity to learn and open conversations around #Generative #AI as it becomes part of everyday discussions within the #sector. The report also includes 👇 ✅ In-depth sector panel discussions on the latest trends and developments in data-driven life sciences and biotech ✅ Engaging breakout sessions covering the state of #techbio in the UK, investment landscape, #data access, AI and data, #engineeringbiology, the future of #genomics, and more.

🚀 A Milestone in AI & Protein Design! In a stunning development from EvolutionaryScale, a group of former Meta scientists led by Alex Rives has launched ESM3—a groundbreaking AI protein design model. Dubbed one of the largest AI models globally, ESM3 has the unique ability to "speak the language of proteins." 👨🔬 Their recent work on a new fluorescent protein is not just a demonstration of ESM3's capabilities but also a sneak peek into the myriad innovations imminent in this field. With a whopping $142M seed investment from Lux Capital, the possibilities seem boundless. 💡 How do you think this evolution in AI-driven protein design will impact other sectors? Pharma, biotech, or maybe something unexpected? Celebrating this monumental step—let's engage in what could be the next big revolution in science and technology! #AI #Biotechnology #Innovation #ProteinDesign #ScienceAdvancements #AIProteinDesign #TechTrends

1st day of #ChiPepTalk Cambridge Healthtech Institute on Protein Sciences is going well! I had a pleasure meeting with Ivanov Alexander R. from Northeastern University, Dikran Khachadourian from Halo Labs and Maria del Carme Pons Royo from Massachusetts Institute of Technology! Here’s an article I wrote when prepping for this seminar - Sample Strategy: A New Perspective on Lab Operations 👇 #Biotech #AI #ProteinScience #Antibody #Biobank https://lnkd.in/etSCuUSu

🚀 Big news in the biotech space! Tempus AI $TEM went public last week, opening at the high end of their range and maintaining a strong performance. With a valuation of $6.7B on 2023 revenues of $531M, Tempus is making waves in genomics and data analysis for disease diagnosis and treatment. However, challenges remain, especially in navigating medical best practices and regulatory hurdles. Dive into our latest blog post for an in-depth analysis of Tempus AI's potential and the crucial elements they're missing for long-term success. 👉 https://lnkd.in/gCCTaW9w #Biotech #Genomics #DataScience #HealthcareInnovation #AI #TempusAI #InvestmentAnalysis #HealthcareTech #IPO

Tempus AI $TEM went public last week, valuing the company at $6.7B on 2023 revenues of $531M. Despite promising growth in genomics and data analysis, the company faces significant challenges, especially in medical best practices, regulatory hurdles, and reimbursement shifts. Their AI product line currently contributes minimally to revenue, and the leadership team lacks crucial medical and regulatory expertise. For a detailed analysis of Tempus AI’s potential and the hurdles they face, read IPO Candy's latest blog post. #Biotech #Genomics #DataScience #HealthcareInnovation #AI #TempusAI #InvestmentAnalysis #HealthcareTech #IPO